| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/29/2010 | WO2010122473A3 A medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it |
| 12/29/2010 | WO2010091649A4 A composition for buccal absorption of nicotine for the purpose of smoking cessation |
| 12/29/2010 | WO2010063998A3 Antibiotic nanomaterial |
| 12/29/2010 | WO2009153305A3 Pharmaceutical compositions of montelukast sodium |
| 12/29/2010 | EP2267909A2 Filters for combined radiotelephone/GPS terminals |
| 12/29/2010 | EP2267445A1 Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject |
| 12/29/2010 | EP2267122A1 Controlled dissolution crosslinked protein crystals |
| 12/29/2010 | EP2267049A1 Block copolymers |
| 12/29/2010 | EP2267026A1 Albumin fusion proteins |
| 12/29/2010 | EP2266889A2 Injection-moulded water-soluble container |
| 12/29/2010 | EP2266719A2 Disposal system for transdermal dosage form |
| 12/29/2010 | EP2266718A2 Disposal system for transdermal dosage form |
| 12/29/2010 | EP2266645A2 External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
| 12/29/2010 | EP2266644A2 External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
| 12/29/2010 | EP2266626A1 Composition for external application comprising transcription factor decoy as active ingredient |
| 12/29/2010 | EP2266621A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266620A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266600A2 Therapeutic composition with a botulinum neurotoxin |
| 12/29/2010 | EP2266599A2 Therapeutic composition with a botulinum neurotoxin |
| 12/29/2010 | EP2266598A1 Method of increasing bone toughness and stiffness and reducing fractures |
| 12/29/2010 | EP2266596A1 Pharmaceutical composition and a method for the production thereof |
| 12/29/2010 | EP2266582A1 Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics |
| 12/29/2010 | EP2266581A1 Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy |
| 12/29/2010 | EP2266579A1 Pharmaceutical composition comprising elvucitavine |
| 12/29/2010 | EP2266578A1 Pharmaceutical composition for preventing and treating bone resorption of different etiology |
| 12/29/2010 | EP2266574A1 Therapeutic use on-demand of formoterol and budesonide |
| 12/29/2010 | EP2266573A1 Fulvestrant formulation |
| 12/29/2010 | EP2266565A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 12/29/2010 | EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist |
| 12/29/2010 | EP2266556A1 Water-based adhesive skin patch comprising ketoprofen lysine salt |
| 12/29/2010 | EP2266553A1 Butenafine hydrochloride-containing aqueous patch |
| 12/29/2010 | EP2266552A2 Methods of inducing terminal differentiation |
| 12/29/2010 | EP2266549A2 Method of making particles for use in a pharmaceutical composition |
| 12/29/2010 | EP2266548A2 Dry powder for inhalation |
| 12/29/2010 | EP2266547A1 Composition for the transdermal delivery of fentanyl |
| 12/29/2010 | EP2266546A1 Process for the preparation of colloidal systems for the delivery of active compounds |
| 12/29/2010 | EP2266545A1 Microencapsulation of essential oils with an enteric matrix |
| 12/29/2010 | EP2266544A2 Method for encapsulating therapeutic substances in cells |
| 12/29/2010 | EP2266543A2 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/29/2010 | EP2266542A2 Controlled release nanoparticulate compositions |
| 12/29/2010 | EP2266541A1 Solid pharmaceutical composition comprising rivaroxaban |
| 12/29/2010 | EP2266540A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 12/29/2010 | EP2266539A2 Methods of treatment using a gastric retained gabapentin dosage |
| 12/29/2010 | EP2266538A2 Rapidly dissolving robust dosage form |
| 12/29/2010 | EP2266537A2 Compositions and methods for treating cancer |
| 12/29/2010 | EP2266536A2 Method of treating acute myocardial infarction |
| 12/29/2010 | EP2266535A2 Controlled release compositions for interferon based on block polymers |
| 12/29/2010 | EP2266534A1 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 12/29/2010 | EP2266533A2 Transdermal delivery rate control using amorphous pharmaceutical compositions |
| 12/29/2010 | EP2265751A2 Methods of attaching a molecule-of-interest to a microtube |
| 12/29/2010 | EP2265728A1 Hemostatic microspheres |
| 12/29/2010 | EP2265605A1 Dexlansoprazole process and polymorphs |
| 12/29/2010 | EP2265292A2 Method for the synthesis of hollow spheres |
| 12/29/2010 | EP2265280A2 Preparation of a pharmaceutical composition for increasing bone mineral density |
| 12/29/2010 | EP2265268A2 Stable fixed dose topical formulation |
| 12/29/2010 | EP2265266A2 Vitamin d compounds and methods for reducing ocular hypertension (oht) |
| 12/29/2010 | EP2265264A1 Transdermal therapeutic system for administration of fentanyl or an analog thereof |
| 12/29/2010 | EP2265263A2 Chewing composition and the use thereof |
| 12/29/2010 | EP2265262A1 Particles comprising polymers with thioester bonds |
| 12/29/2010 | EP2265261A1 Drug delivery systems comprising weakly basic drugs and organic acids |
| 12/29/2010 | EP2265260A2 Solid dosage form for treating headaches |
| 12/29/2010 | EP2265259A1 Rapidly disintegrating oral compositions of tramadol |
| 12/29/2010 | EP2265258A2 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 12/29/2010 | EP2265257A2 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 12/29/2010 | EP2265256A1 Dithiocarbamate metal chelates and methods of making and using thereof |
| 12/29/2010 | EP2265255A1 Formulations of vitamin k analogs for topical use |
| 12/29/2010 | EP2265254A2 Suspension formula for carbon adsorbents |
| 12/29/2010 | EP2265253A2 Oral dosage form containing a pyridinol derivative |
| 12/29/2010 | EP2265252A2 Ophthalmic preparation containing a pyridinol derivate |
| 12/29/2010 | EP2265251A2 Pharmaceutical compositions having desirable bioavailability |
| 12/29/2010 | EP2265250A2 Enhanced transmucosal composition and dosage form |
| 12/29/2010 | EP2265126A1 Methods and compositions for controlled delivery of phytochemical agents |
| 12/29/2010 | EP2142174B1 Stable aqueous g-csf formulations |
| 12/29/2010 | EP2131822B1 Divalent metal-ion loaded nano-transport system having a dendritic architecture useful for therapy |
| 12/29/2010 | EP2120884B1 Pharmaceutical composition |
| 12/29/2010 | EP1978940B1 Biologically active composition comprising ethylcellulose |
| 12/29/2010 | EP1962836B1 Treatment of length dependent neuropathy |
| 12/29/2010 | EP1902712B1 Use of levo-ornidazole for preparing antiparasitic infection drug |
| 12/29/2010 | EP1886169B1 Ophthalmic devices for sustained delivery of active compounds |
| 12/29/2010 | EP1771199B1 Long-acting colloidal insulin formulation and preparation thereof |
| 12/29/2010 | EP1722761B1 Method of producing microparticles |
| 12/29/2010 | EP1621202B1 Freeze-dried preparation containing methylcobalamin and process for producing the same |
| 12/29/2010 | EP1576959B1 Softgel of nlkj (neutral lipids obtained from kernels of job's tears) for treating prostate diseases |
| 12/29/2010 | EP1545429B1 Compositions containing citric acid for the treatment of nail fungal infections |
| 12/29/2010 | EP1542658B1 Pharmaceutical compositions comprising an opioid analgesic |
| 12/29/2010 | EP1441727B1 Depot formulations of iloperidone and a star polymer |
| 12/29/2010 | EP1387673B1 Abuse-resistant controlled-release opioid dosage form |
| 12/29/2010 | EP1372603B1 Topical application for treating toenail fungus |
| 12/29/2010 | EP1370530B1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical |
| 12/29/2010 | EP1345611B1 An antibiotic/analgesic formulation and a method of making this formulation |
| 12/29/2010 | EP1286657B1 Nasal ointment based on white petroleum jelly |
| 12/29/2010 | EP1197209B1 Percutaneously absorbable preparations |
| 12/29/2010 | EP1183022B1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 12/29/2010 | EP1077678B1 Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| 12/29/2010 | CN1977868B Ginkgo biloba leaf total terpene lactone extract, and its preparing method, medicinal composition and use |
| 12/29/2010 | CN1969032B Method of inhibiting formation of volatile aldehydes and/or decomposition of fatty acids and use thereof |
| 12/29/2010 | CN1956707B Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-D-glutamic acid (LK-423) |
| 12/29/2010 | CN1935262B Use of red Nocardia cyto skeleton for preparing anti human papillomavirus medicine |
| 12/29/2010 | CN1899361B Zhenqi medicinal composition and its preparation |
| 12/29/2010 | CN1895371B Inebriant for treating scald and burn |